RxDoctor Payments Data

Michael Berlowitz, MD

Interventional Cardiology · Lewiston, MENPI 1902871817

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $533 of the $631 with a category attached, or 84.5%. 8 manufacturers reported payments, led by Abbott at 37.1% of the total. That places this record below the midpoint for interventional cardiology clinicians in ME, where the typical reported total is $2,318.

$631in general payments, 2019–2025

Across 18 payments — averaging $35.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$234
  • Abiomed$158
  • AstraZeneca$141
  • Teleflex LLC$27
  • Medtronic$18
  • Canon Medical Systems USA, Inc.$18
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$53384%
  • Education$9816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$631 in reported general payments places this provider in the 25th percentile of 21 interventional cardiology providers in Maine.

See all interventional cardiology providers in Maine

Medicare billing

Part B allowed, 2024
$48,674
Medicare patients
499
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$47,435
XareltoRivaroxaban36$28,354
EntrestoSacubitril/Valsartan20$20,911
Praluent PenAlirocumab12$10,158
Valsartan90$4,602
Repatha SyringeEvolocumab12$3,826
Metoprolol Succinate141$2,769
Carvedilol119$1,204
Ranolazine ErRanolazine12$1,064
Nebivolol Hcl12$931
Rosuvastatin Calcium30$819
ClopidogrelClopidogrel Bisulfate57$654
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19$624
Losartan Potassium42$594
Amlodipine Besylate56$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18$20,91120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 21 interventional cardiology providers in Maine.

Other interventional cardiology in Lewiston

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →